Equities

Entero Therapeutics Inc

ENTO:NAQ

Entero Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.07
  • Today's Change0.076 / 7.65%
  • Shares traded49.45k
  • 1 Year change-96.48%
  • Beta1.3529
Data delayed at least 15 minutes, as of Jul 05 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.

  • Revenue in USD (TTM)0.00
  • Net income in USD-6.44m
  • Incorporated2014
  • Employees15.00
  • Location
    Entero Therapeutics Inc777 Yamato Road, Suite 502BOCA RATON 33431United StatesUSA
  • Phone+1 (561) 589-7020
  • Websitehttps://enterothera.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ENTO:NAQ since
announced
Transaction
value
ImmunogenX IncDeal completed18 Dec 202318 Dec 2023Deal completed-75.79%--
Data delayed at least 15 minutes, as of Jul 05 2024 20:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Regen BioPharma Inc236.58k-851.69k2.47m1.00------10.44-0.2271-0.22710.0633-1.260.8644--3.98236,580.00-327.54-104.36---------378.93-275.00---1.32----0.441618.79-58.11------
Cingulate Inc0.00-22.50m2.48m13.00--0.5252-----22.66-22.660.000.64190.00----0.00-355.56---1,198.96-------------33.880.0054-------33.14------
Qrons Inc0.00-763.52k2.53m2.00---------0.0562-0.05620.00-0.10780.00----0.00-18,782.78-1,513.45---------------19.02---------7.61------
SenesTech Inc1.38m-7.51m2.55m25.00--0.5524--1.85-15.21-15.210.71890.89610.27180.93913.2955,000.00-148.36-118.53-178.99-140.6142.3339.40-545.82-1,357.865.69--0.0378--17.0832.0620.47---9.02--
Exicure Inc500.00k-13.34m2.61m6.00--1.18--5.21-1.56-1.560.05820.25510.0289----83,333.34-76.97-41.52-91.14-55.78-----2,667.20-290.95----0.00---100.00---555.07------
Entero Therapeutics Inc0.00-6.44m2.65m15.00--0.1339-----51.90-51.900.0038.450.00----0.00-12.74-295.92-14.01-1,599.51-----------265.690.0802-------7.55------
Tharimmune Inc0.00-8.89m2.67m2.00--0.3791-----111.65-111.650.008.970.00----0.00-130.60---173.40--------------0.00-------9.98------
Qualigen Therapeutics Inc0.00-12.48m2.69m4.00---------2.46-2.640.00-0.39230.00----0.00-118.15---364.72--21.30---------7.41--------10.22------
Tron Pharmaceuticals Inc1.01m-549.47k2.75m50.00------2.73-0.0034-0.00340.0062-0.0508------20,191.00--------60.28---110.51--0.0417-433.32----0.3272---39.70------
Revelation Biosciences Inc0.00-8.96m2.82m9.00--0.2982-----32.09-32.090.005.800.00----0.00-54.61---91.95--------------0.00------98.89------
Bio Path Holdings Inc0.00-13.96m2.83m10.00---------27.39-27.390.00-3.480.00----0.00-216.97-70.80-390.65-76.87---------------------15.94------
Kiromic Biopharma Inc0.00-24.99m2.86m31.00---------29.21-29.210.00-3.810.00----0.00-171.18-161.49---213.01-----------15.691.87-------35.90--177.42--
Altamira Therapeutics Ltd117.71k-8.11m2.87m10.00--0.2624--24.36-31.49-26.580.23964.880.015134.0532.3011,771.21-103.88-73.80-6,364.67-123.19-87.90---6,892.99--1.38-4.360.0152------61.02------
Virax Biolabs Group Ltd0.00-1.71m2.88m5.00---------1.50-1.500.00-0.8568------0.00----------------0.0223-112.29-----100.00---162.50------
Alzamend Neuro Inc0.00-12.40m2.88m4.00---------1.87-1.870.00-0.5720.00----0.00-267.15---880.90-------------1,352.90---------20.35------
Data as of Jul 05 2024. Currency figures normalised to Entero Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

1.46%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 202427.00k0.98%
Geode Capital Management LLCas of 31 Mar 202410.85k0.39%
Tower Research Capital LLCas of 31 Mar 20242.39k0.09%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 202412.000.00%
U.S. Bank NA (Cincinnati Ohio Investment Management)as of 31 Mar 20241.000.00%
Kathleen S. Wright Associates, Inc.as of 31 Mar 20241.000.00%
Wells Fargo Clearing Services LLCas of 31 Mar 20241.000.00%
UBS Securities LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.